^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tigatuzumab (CS-1008)

    i
    Other names: CS-1008 , TRA 8, CS 1008
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    7ms
    Peg-lipid-modified agonistic antibody against tumor necrosis factor receptor family elicits superior apoptosis-inducing activity against human carcinoma. (PubMed, Bioorg Med Chem Lett)
    The chemically modified TRA-8 antibody [anti-death receptor 5 (DR5) antibody] with PEG-lipid (DSPE-PEG) demonstrated significant cytotoxic activity in vitro without the need for crosslinking with a secondary antibody, which is typically required...Nevertheless, by designing new PEG-lipids that are intended to be resistant to enzymatic degradation, we were able to prevent this degradation and restore the cytotoxic activity of the modified antibody. These findings provide valuable insights for the design of PEG-lipid-modified antibodies and suggest their potential effectiveness in enhancing cancer therapy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
    |
    tigatuzumab (CS-1008)
    over1year
    Identification and validation of an immune-relevant risk signature predicting survival outcome and immune infiltration in uveal melanoma. (PubMed, Int Ophthalmol)
    The identified immune risk signature was demonstrated to be associated with the favorable immune infiltration, prognosis and immunotherapeutic efficacy, which may provide clues for survival evaluation and immune treatment.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    tigatuzumab (CS-1008)